How it was built
- The approach
Every load-bearing claim comes from a named guideline, trial, or meta-analysis, with the evidence dots (●●●●● = strong and replicated, down to ○○○○○ = essentially unproven) reflecting study design, size, and replication. Figures are group averages; individuals vary widely. This is educational, not a diagnosis or a prescription — and the frontier sections (CAR-T, tolerance, the experiments) are graded as early precisely so the excitement doesn't outrun the evidence.
- The key sources
What it is & causes: the ACR/EULAR materials and reviews on RA pathogenesis, the shared-epitope/smoking/ACPA literature, and the mucosal-origins and pre-clinical-RA work. Diagnosis & strategy: the 2010 ACR/EULAR classification criteria, the anti-CCP performance studies, the EULAR treat-to-target recommendations, and the TICORA trial. Drugs: the 2021 ACR and EULAR treatment guidelines, the RACAT and TEAR triple-therapy trials, and ORAL Surveillance (the JAK safety trial) with the resulting FDA boxed warning. Lifestyle & supplements: the Mediterranean-diet and omega-3 RA trials (Proudman), the Kjeldsen-Kragh fasting study, the SARAH hand-exercise trial, the smoking-RA literature, and the NCCIH natural-products reviews. Remission & the frontier: the RETRO tapering trial, the APIPPRA/PRAIRI/StopRA intercept trials, the RESET-RA vagus-nerve-stimulation trial, and the Schett CAR-T 'immune reset' work.